Glooko partners with Novo Nordisk for digital diabetes management
BAGSVAERD, Denmark, and MOUNTAIN VIEW, Calif. – Novo Nordisk and Glooko have announced they will work together to deliver jointly-developed and branded digital health solutions for people with diabetes.
The non-exclusive collaboration will combine Novo Nordisk’s deep knowledge of diabetes with Glooko’s digital platform and data analytics expertise.
“We are excited to partner with Glooko and to take another step towards delivering digital health offerings that help people with diabetes to improve their blood glucose control,” said Christian Kanstrup, senior vice president, Stategy, Access & Marketing, Novo Nordisk, in a statement. “Working in partnerships will furthermore enhance our ability to demonstrate the real-world value of our portfolio of diabetes treatments.”
Building on Glooko’s mobile and web platforms, the companies plan to deliver personalized, digital services to support people with diabetes in areas including treatment adherence and blood glucose management. The partnership’s joint offerings will also assist health care professionals to engage and manage patients with the aid of population-wide data reporting. By integrating these offerings within its Digital Health Platform developed with IBM Watson Health, Novo Nordisk hopes to generate increasingly valuable insights into diabetes management and treatment outcomes.
Glooko is a population health platform for diabetes management that enables people with diabetes to track and better manage their condition using mobile, web and cloud technology. Glooko’s mobile app enables individuals to sync their data from diabetes and exercise devices, including blood glucose meters. The company’s population health application enables care teams to remotely support people with diabetes and is focused on improving patient satisfaction and outcomes at a lower cost.
“Glooko’s partnership with Novo Nordisk aims to empower tens of millions of patients with digital tools to make diabetes management easier,” said Rick Altinger, Glooko CEO, in a statement. “We look forward to delivering jointly-branded capabilities that will enhance the collaboration between patient and healthcare professionals and enable us to provide joint offerings to people living with diabetes around the world.”
Cogilex launches health search engine
MONTREAL – Cogilex R&D has launched Seenso Health, a search engine that ranks web pages intelligently based on the meaning of their content. “Our goal is to make medical search easier and better,” said Dr. Mei Chen, Cogilex CEO and chief scientist, in a statement. The company’s goal is to provide high-quality medical information in a way that helps users better understand their health problems and make wiser medical decisions. Seenso Health also mimics the behavior of a knowledgeable and helpful guide by offering users knowledge maps of key information and a guided exploratory interface for expanding the search. “When people act on fragmented and inadequate information, it can lead to counterproductive feelings, decisions and actions, and this has become the cause of increasing concern from both health professionals and the search engine community,” said Chen. “Our search engine highlights a range of issues important to a health topic and it can potentially help users form a more comprehensive view and make better informed medical decisions.”
TriageLogic launches nurse call app
JACKSONVILLE, Fla. – Telemedicine company TriageLogic has launched a mobile app and website portal for businesses that allows employees to request a call from a nurse for themselves or a family member. Through Continuwell, nurses use doctor-written guided protocols to evaluate callers and determine the care needed to resolve their symptoms. “One of the biggest challenges for telehealth is to get people to actually make the call,” said Charu Raheja, Ph.D., Continuwell CEO, in a statement. “Our nurses eliminate that barrier because they are free to call and nurses are traditionally the first line of care in medicine.” If the caller’s symptoms require a doctor evaluation or a prescription, the nurses transfer the caller to one of the company’s U.S. board-certified doctors. The company says the platform will decrease employee sick days and decrease health care costs with the 24/7/365 service.
FDA issues cybersecurity notice for St. Jude cardiac devices
SILVER SPRING, Md. – The U.S. Food and Drug Administration issued a notice that cybersecurity vulnerabilities have been identified in St. Jude Medical’s implantable cardiac devices and the Merlin@home Transmitter. “The FDA has reviewed information concerning cybersecurity vulnerabilities associated with St. Jude Medical’s Merlin@home Transmitter and has confirmed that these vulnerabilities, if exploited, could allow an unauthorized user, i.e., someone other than the patient’s physician, to access a patient’s RF-enabled implanted cardiac device by altering the Merlin@home Transmitter,” the notice said. The transmitter could then be used to modify programming commands to the implanted device, which could result in rapid battery depletion or administration of inappropriate pacing or shocks, said the FDA. St. Jude Medical has developed a software patch that addresses and reduces the risk of cybersecurity vulnerabilities.
Intent Solutions names Gastfriend to Advisory Board
ATLANTA – Intent Solutions, maker of the TAD medication dispenser, has named Dr. David Gastfriend to its advisory board. In his new role, Gastfriend will help the company optimize TAD for improving medication adherence, as well as advise the company on leveraging the various stakeholders in the health care system to achieve change and improvements in patient outcomes. “Intent Solutions has a broad role to play in modern medicine,” said Gastfriend in a statement. “TAD stands to become a breakthrough in pharmacologic research, including FDA trials, ensuring that medicines being studied are truly being taken by patients as intended. This is a huge unknown, currently, for which we have poor methods of validation, and yet it can make or break an otherwise excellent new treatment.”
DarioHealth raises $5.1M to speed market adoption
BOSTON – Glucose meter maker DarioHealth recently announced $5.1 million in aggregate funding. “With this funding, we will accelerate adoption of our innovative and user-friendly remote glucose monitor platform across current markets and also expand into new geographies, such as Germany, in 2017,” said Erez Raphale, DarioHealth chairman and CEO, in a statement. The company will use the funding to promote the platform and further penetrate U.S. and other markets, as well as provide working capital and other general purposes.